tiprankstipranks
Karyopharm narrows 2024 revenue view to $145M-$155M from $145M-$160M
PremiumThe FlyKaryopharm narrows 2024 revenue view to $145M-$155M from $145M-$160M
18d ago
Karyopharm Therapeutics Updates Phase 3 SENTRY Trial
Premium
Company Announcements
Karyopharm Therapeutics Updates Phase 3 SENTRY Trial
23d ago
Karyopharm changes endpoint in Phase 3 trial of selinexor in myelofibrosis
Premium
The Fly
Karyopharm changes endpoint in Phase 3 trial of selinexor in myelofibrosis
23d ago
Karyopharm reports Q2 EPS (20c), consensus (30c)
PremiumThe FlyKaryopharm reports Q2 EPS (20c), consensus (30c)
4M ago
Karyopharm Therapeutics INC (KPTI) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
Karyopharm Therapeutics INC (KPTI) Q2 Earnings Cheat Sheet
4M ago
Karyopharm granted FDA orphan designation in Ewing sarcoma
Premium
The Fly
Karyopharm granted FDA orphan designation in Ewing sarcoma
5M ago
Karyopharm files to sell 45.78M shares of common stock for holders
PremiumThe FlyKaryopharm files to sell 45.78M shares of common stock for holders
6M ago
Karyopharm Therapeutics Enhances Financial Stability and Liquidity
Premium
Company Announcements
Karyopharm Therapeutics Enhances Financial Stability and Liquidity
7M ago
Karyopharm still sees 2024 revenue $140M-$160M, consensus $146.52M
Premium
The Fly
Karyopharm still sees 2024 revenue $140M-$160M, consensus $146.52M
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100